After a year of semaglutide use, the participants saw a notable decrease in their 10-year ASCVD risk, dropping from an average of 7.64% to 6.26%a reduction of 1.38%
Last reviewed: June 9, 2026 Last updated: June 9, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
For most patients, Ozempic side effects will lessen in severity over time
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia